EntryPoint Capital’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding CPRX
VCM
DM
VPM
EntryPoint Capital's CPRX Position: Q1 2026 in Review
EntryPoint Capital increased its Catalyst Pharmaceutical (CPRX) stake by 51% in Q1 2026, buying an estimated $157K and bringing the position to 19,539 shares worth $484K. The position accounts for 0.14% of the portfolio, ranked #265.
EntryPoint Capital first reported a position in CPRX in Q4 2023 and has held it in 6 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- EntryPoint Capital held 19,539 shares of Catalyst Pharmaceutical worth $484K as of Q1 2026.
- EntryPoint Capital bought 6,608 Catalyst Pharmaceutical shares in Q1 2026, an estimated $157K.
- Catalyst Pharmaceutical made up 0.14% of EntryPoint Capital's portfolio in Q1 2026, its #265 holding.
- EntryPoint Capital first reported a position in Catalyst Pharmaceutical in Q4 2023 and has held it in 6 quarters since.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.